NCT01923870View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Secondary Hypogonadism
Interventions
DRUG

Androxal 25 mg

Trial Locations (1)

33014

Miami

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01923870 - Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function | Biotech Hunter | Biotech Hunter